through hydrolysis of semenogelin. Desquamation of the skin is likely controlled by KLK5, KLK7 and KLK14, which are expressed in the outermost layer of the epidermis and cleave cellular adhesion proteins. Additionally, KLK6 and KLK8 are associated with neuronal plasticity in the central nervous system. Genes There are 15 known human tissue kallikreins: KLK1, KLK2, KLK3, KLK4, KLK5, KLK6, KLK7, KLK8, KLK9, KLK10, KLK11, KLK12, KLK13, KLK14, KLK15 Clinical significance Kallikrein-related peptidases are targets of active investigation by drug researchers as possible biomarkers for cancer. Prostate-specific antigen (PSA; hk3, human kallikrein gene 3) and human glandular kallikrein (hK2) are used as tumor markers for prostate cancer. Ecallantide, lanadelumab, and berotralstat are FDA-approved drugs that inhibit kallikrein and can be used for managing Hereditary Angioedema. See also Prekallikrein Kinin-kallikrein system Kinin Aprotinin List of cutaneous conditions References External links The MEROPS online database for peptidases and their inhibitors: S01.212 EC 3.4.21 Kinin–kallikrein system Urticaria and angioedema